Amgen's Horizon Acquisition Offers Multiple Advantages: Tax Breaks, Shield From Drug Pricing Negotiations
Portfolio Pulse from Vandana Singh
The U.S. Federal Trade Commission (FTC) has approved Amgen Inc's acquisition of Horizon Therapeutics Plc. This decision could provide Amgen with a portfolio of drugs shielded from fresh pricing negotiations and possible tax relief benefits. The acquisition focuses on 'orphan drugs' which are not impacted by the Inflation Reduction Act (IRA) introduced in 2022. The Horizon acquisition could also offer tax breaks linked to Irish manufacturing units.
September 05, 2023 | 5:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amgen's acquisition of Horizon Therapeutics could shield it from fresh pricing negotiations and offer tax relief benefits.
The FTC's approval of Amgen's acquisition of Horizon could provide Amgen with a portfolio of drugs shielded from fresh pricing negotiations and possible tax relief benefits. This could positively impact Amgen's financial position in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Horizon Therapeutics has been acquired by Amgen, which could provide Amgen with a portfolio of drugs shielded from fresh pricing negotiations.
Horizon's acquisition by Amgen could shield Amgen from fresh pricing negotiations. However, the direct impact on Horizon's financial position is not clear from the news.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80